Repligen Corporation (RGEN)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $10.41B
Last updated: Nov 17, 2026 at 4:15 PM ET
Repligen Corporation (RGEN) Statistics
Repligen (RGEN) has a market cap of $10.41B and an enterprise value of $10.24B. Its return on invested capital of 0.10% compares with a 7.13% median across 9 similar companies.
Total Valuation
Enterprise value is 1.63% below the market cap, as cash exceeds debt.
| Market Cap | $10.41B |
|---|---|
| Enterprise Value | $10.24B |
| Latest price (Nov 17, 2026) | $162.18 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 27, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.4x and 4.4x. Its year-end P/E ranged from 51.6x to 138.6x from 2016 to 2025.
| P/E Ratio | 79.5x |
|---|---|
| Forward P/E | 76.7x |
| P/S Ratio | 11.4x |
| Forward P/S | 12.3x |
| P/B Ratio | 4.4x |
| P/TBV Ratio | 13.4x |
| P/FCF Ratio | 86.0x |
| P/OCF Ratio | 80.1x |
| PEG Ratio | 3.2 |
Enterprise Valuation
Counting debt and cash, the company is valued at 90.7x EBITDA and 84.4x free cash flow.
| EV / Sales | 12.7x |
|---|---|
| EV / EBITDA | 90.7x |
| EV / FCF | 84.4x |
Price Statistics
The stock is up 6.44% over 52 weeks and trades 8.33% below its 50-day average.
| Beta (1Y) | 1.21 |
|---|---|
| 52-Week Change | +6.44% |
| 1-Month Change | -8.08% |
| 3-Month Change | -8.04% |
| 6-Month Change | +49.45% |
| 5-Year Change | -39.09% |
| 10-Year Change | +519.32% |
| Total Return (1Y) | +6.44% |
| Total Return (3Y CAGR) | +2.50% |
| Total Return (5Y CAGR) | -10.35% |
| Return vs SPY (1Y) | -5.60% |
| Max Drawdown (1Y) | -40.28% |
| Max Drawdown (3Y) | -50.64% |
| Sharpe Ratio (1Y) | 0.13 |
| Correlation with SPY (1Y) | 0.36 |
| 50-Day Average | $176.92 |
| 200-Day Average | $145.39 |
| 52-Week Range | $100.99 to $198.87 |
| RSI (14 Days) | 39.6 |
| Average Volume (20 Days) | 1.24M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.88x current liabilities, and total debt is 0.27x shareholder equity.
| Current Ratio | 9.88x |
|---|---|
| Quick Ratio | 8.43x |
| Debt / Equity | 0.27x |
| Debt / EBITDA | 5.62x |
| Debt / FCF | 5.23x |
| Interest Coverage | 0.18x |
Returns and Efficiency
Return on invested capital is 0.10% over the last 12 months, against a 5-year average of 2.37%.
| Return on Equity (ROE) | -0.56% |
|---|---|
| Return on Assets (ROA) | -0.40% |
| Return on Invested Capital (ROIC) | 0.10% |
| ROE (5Y Average) | 3.98% |
| ROA (5Y Average) | 2.96% |
| ROIC (5Y Average) | 2.37% |
| Asset Turnover | 0.28x |
| Inventory Turnover | 2.02x |
| Receivables Turnover | 5.22x |
| Cash Conversion Cycle | 221 days |
Scores
RGEN has an Altman Z-Score of 7.54, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.54 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $805.61M over the last 12 months is up 13.80% from the 12 months before.
| Revenue | $805.61M |
|---|---|
| Revenue Growth (YoY) | +13.80% |
| Gross Profit | $433.14M |
| Operating Income | $18.24M |
| Pretax Income | $8.23M |
| Net Income | -$11.80M |
| EBITDA | $99.27M |
| Reported EPS (TTM) | $2.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 71.33% of the $2.93B in total assets.
| Cash and Equivalents | $726.96M |
|---|---|
| Total Debt | $557.85M |
| Net Cash | $169.11M |
| Net Cash Per Share | $2.99 |
| Working Capital | $1.12B |
| Shareholder Equity | $2.09B |
| Book Value Per Share | $36.98 |
| Tangible Book Value | $686.13M |
| Tangible Book Per Share | $12.13 |
| Total Assets | $2.93B |
| Total Liabilities | $834.67M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $23.14M of capital spending, operating cash flow left $106.72M of free cash flow.
| Operating Cash Flow | $129.86M |
|---|---|
| Capital Expenditures | $23.14M |
| Free Cash Flow | $106.72M |
| FCF Per Share | $1.68 |
| Depreciation and Amortization | $115.82M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 2.26%, against a 5-year average of 12.49%.
| Gross Margin | 53.77% |
|---|---|
| Operating Margin | 2.26% |
| Pretax Margin | 1.02% |
| Net Margin | -1.47% |
| EBITDA Margin | 12.32% |
| FCF Margin | 13.25% |
| Gross Margin (5Y Average) | 50.97% |
| Operating Margin (5Y Average) | 12.49% |
| Net Margin (5Y Average) | 10.11% |
Growth
Revenue fell 2.70% a year over 3 years, and EPS 19.52% a year.
| Revenue Growth (3Y CAGR) | -2.70% |
|---|---|
| Revenue Growth (5Y CAGR) | +15.05% |
| EPS Growth (3Y CAGR) | -19.52% |
| EPS Growth (5Y CAGR) | +0.60% |
| FCF Growth (3Y CAGR) | +2.48% |
| FCF Growth (5Y CAGR) | +18.51% |
| Operating Income Growth (3Y CAGR) | -37.38% |
| Book Value Per Share Growth (2Y CAGR) | +2.88% |
| Tangible Book Per Share Growth (2Y CAGR) | +2.36% |
Dividends and Yields
RGEN does not pay a dividend. Its free cash flow yield is 1.16%.
| Earnings Yield | 1.26% |
|---|---|
| FCF Yield | 1.16% |
| Shareholder Yield | 0.00% |
Peer Position
Against 11 similar companies, RGEN has the 2nd highest P/E and the 2nd highest P/S.
P/E RatioPeer median 20.7x
P/S RatioPeer median 2.9x
ROICPeer median 7.13%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.59%
| P/E Ratio | 79.5x vs 20.7x median |
|---|---|
| P/S Ratio | 11.4x vs 2.9x median |
| ROIC | 0.10% vs 7.13% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.80% vs +7.59% median |
Analyst Forecast
Consensus estimates put revenue growth at 20.37% and EPS growth at 24.54% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +20.37% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +24.54% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RGEN
What is RGEN's market cap?
Repligen has a market cap of $10.41B. Its enterprise value, which adds debt and subtracts cash, is $10.24B.
What is RGEN's P/E ratio?
Repligen has a trailing P/E ratio of 79.5x and a forward P/E of 76.7x.
How many shares of RGEN are outstanding?
Repligen has 56.56M shares outstanding. The count is up 0.52% from a year earlier.
Does RGEN pay a dividend?
No. Repligen does not pay a dividend.
How much debt does RGEN have?
Repligen has $557.85M of total debt and $726.96M of cash and equivalents, a net cash position of $169.11M.
RGEN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts